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Reconstructive transplantation has emerged as clinical reality over the past decade. Long-
term graft acceptance has been feasible in extremity and facial vascularized composite
allotransplantation (VCA) under standard immunosuppression. Minimizing overall burden
of lifelong immunosuppression is key to wider application of these non-life saving grafts.
Allograft tolerance is the holy grail of many cell-based immunomodulatory strategies.
Recent protocols using mesenchymal stem cells from bone marrow and adipose tissue
offer promise and potential in VCA. This article provides an overview of the experimental
basis, the scientific background and clinical applications of stem cell-based therapies in the
field of reconstructive allotransplantation.
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INTRODUCTION
Complex reconstructions after major trauma are limited by avail-
able tissues, morbidity from extensive surgery, prolonged rehabil-
itation, suboptimal results, and costs of multiple surgeries. For
such intricate injuries, vascularized composite allotransplanta-
tion (VCA) can achieve optimal restoration of tissue deficits with
improved functional and esthetic results, enabling social and pro-
fessional reintegration. During the past decade, more than 100
reconstructive transplant procedures have been performed around
the world, including over 90 hand and 24 facial transplants with
encouraging overall outcomes (1–3).
Like solid organ transplants,VCA requires long-term multidrug
immunosuppression to prevent graft rejection mediated predom-
inantly by the highly immunogenic skin component in these allo-
grafts. Medication toxicity could result in metabolic, infectious, or
neoplastic complications. VCA is inherently different from solid
organ transplantation in its non-life saving, yet life-enhancing
impact on recipients. Further,unlike solid organs,clinical success is
dictated not only by graft acceptance and survival, but also by nerve
regeneration, which determines ultimate functional outcomes.
These characteristics of VCA, drive the debate focused on the
risks of lifelong immunosuppression mandated for graft survival
balanced against the benefits of functional and quality of life out-
comes. Thus, implementation of cellular therapies that integrate
the concepts of immune regulation for graft acceptance with those
of nerve regeneration could optimize the outcomes of these recon-
structive modalities and minimize overall burden of immuno-
suppression. Such strategies could expand clinical feasibility and
realize routine applicability of reconstructive transplantation.
Mesenchymal stem cells (MSCs) are pluripotent cells that are
present in multiple tissues, including bone marrow (BM), adipose
tissue, skin, muscle, blood, and placenta and can be isolated and
expanded ex vivo. MSCs are capable of differentiation in vitro along
multiple mesenchymal lineages such as osteocytes, chondrocytes,
myocytes, adipocytes, and Schwann cells (SC) thereby emerging
as a promising tool for tissue engineering and cell therapy.
Current literature on MSCs points to a wide range of immuno-
logical functions and interactions with other cell types (4, 5).
Recent data support findings that MSCs mediate their actions
through multiple mechanisms including paracrine effects. Various
groups have shown some key differences between adipose-derived
MSCs (AD-MSCs) and bone marrow derived MSCs (BM-MSCs)
in vitro and in vivo (6–8). In particular, it has been demonstrated
that MSCs have the capacity to suppress T cell activation and pro-
liferation (9). Compared to BM, adipose tissue is a rich source of
MSCs with up to 10-fold higher yield of MSCs (10). More recent
publications demonstrate that AD-MSCs might also have higher
immunomodulatory and immunosuppressive potential in vitro as
compared to BM-MSCs (11–20). The ease of procurement of large
volumes of AD-MSCs through techniques such as liposuction is an
important benefit because of expeditious approach and minimal
morbidity. Depending on time considerations for cell expansion,
the overall duration of cell retrieval to cell infusion could be signif-
icantly shortened for AD-MSCs as compared to MSCs from other
sources.
There is a growing complement of first in human studies
addressing potential of MSC based cell therapies in autoimmune
diseases, facilitation of hematopoietic stem cell engraftment in
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BM transplantation and in solid organ transplantation (4, 21, 22).
Recent experimental and clinical studies highlight their potential
for immunomodulation, tolerance induction, and prophylaxis and
treatment of graft versus host disease (GvHD) (23–25). In VCA,
the efficacy and effectiveness as well as mechanisms and outcomes
of such therapies may be affected by the antigenicity of the skin
component (26), as or by the differential tissue composition of
these grafts.
IMMUNOLOGICAL FUNCTION OF MSCs
The effects of MSCs on innate and adaptive immunity have been
reported in the literature (4, 5). MSCs modulate the innate func-
tion of monocytes, macrophages, natural killer (NK) cells, and
dendritic cells (DCs). They are capable of modifying the matura-
tion of DC, thereby inhibiting their antigen-presenting function
and inducing the generation of tolerogenic DCs. This results
in downregulated MHC II and chemokine expression (27–30).
MSCs show intermediate expression of MHC I and do not express
MHC II on their surface, which reduces their antigenicity. How-
ever the intracellular MHC II can become relevant when NK lyse
transplanted MSCs (31, 32). In addition, MSCs also affect innate
immunity through HLA-G expression leading to inhibition of NK
cells and reduction of IFN-g expression (33, 34). English et al. (35)
have shown that MSCs can directly induce regulatory T cell (Treg)
generation. Mediators of Treg generation include indoleamine
2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and IFN-g (4).
However, MSCs inhibit the activation of cytotoxic lymphocytes
and immunoglobulin production through activated and prolifer-
ating B cells (36). The nitric oxide (NO) system as well as factors
involved in stem cell recruitment like SDF-1, growth factors like
VEGF and cytokines like IL-6, IL-8, and IL-10 have been shown
to be important players in MSC dependent effects on adaptive
immune responses (4, 5) (Figure 1).
MSCs PROMOTE NERVE REGENERATION
The functional advantages of VCA over prosthetic fitting rely
not only on motor recovery but also sensory recovery follow-
ing regeneration of peripheral nerves and reintegration of neu-
ronal pathways into the premotor cortex of the brain. MSCs have
shown promise in improving clinical and electrophysiological out-
comes in animal models of peripheral nerve injury (37–39). In
comparison to local delivery, some groups have demonstrated
significantly accelerated functional neuronal recovery following
systemic administration of MSCs (40). The postulated mecha-
nisms for such outcomes could include direct and paracrine effects
(38, 41).
MSC USE IN ALLOTRANSPLANTATION
Bartholomew et al. (9) first described prolongation of skin graft
survival after allotransplantation in primates with a single applica-
tion of expanded BM-MSCs at day 0. Sbano et al. (42) also reported
similar results with cultured BM-MSC administered on day 0 and
3 in a rat model. Skin graft survival was prolonged, although grafts
were rejected without supplementary immunosuppression.
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FIGURE 1 | Immunological Function of MSCs on different cell types of
the innate and adaptive immunosystem. MSC, mesenchymal stromal
cell, characterized by surface antigens CD29, CD73, CD90 (CD105), MHC
I; cell types: B cells, T Cells, Treg; regulatory T cells; DC, dendritic cells
(tolerogenic, i/m, immature/mature), monocytes, macrophages, NK,
natural killer cells. Arrows indicate activation or induction, T-bars indicate
blockade of function or activation, in particular inhibition of proliferation,
differentiation, cytotoxicity, maturation. The NO system is closely involved
in creating an immunosuppressive microenvironment. Via an indirect way
the generation of tolerogenic DCs induces Tregs. MSCs can also directly
activate Treg generation. These Tregs play a significant role in the
development of tolerance.
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Solari et al. (43) demonstrated long-term islet allograft survival
in rats using syngeneic MSCs. In this study, repetitive applica-
tion of syngeneic BM-MSCs was superior to allogeneic BM-MSCs.
However, long-term tolerance could only be achieved in 40%, and
cells were expanded up to P8. Their inherent immunomodula-
tory function has promoted use of MSCs in BM transplantation,
solid organ transplantation, and treatment of GvHD (30). BM-
MSCs have been used in experimental animal heart, liver, kidney,
and islet transplantation (14, 30, 43–49). Immunomodulation was
related to the suppression of alloreactive effector lymphocytes (50)
through expression of a variety of cytokines (51–53) (Figure 1)
and generation of CD4/CD25/FoxP3 Tregs that achieved long-
term tolerance in animal studies via adaptive immune mechanisms
(31, 50). Data on AD-MSCs in solid organ transplantation is
scarce; however sources for MSCs other than BM have been sup-
ported/investigated (54). In addition, studies have confirmed the
multifaceted properties of MSCs including their potential as part
of induction therapy (55), in GvHD (56), tolerance induction (55,
57), and facilitating engraftment of BM transplants (58, 59). Sev-
eral clinical trials have demonstrated their immunosuppressive
function that could have potential in autoimmune disease (32, 60,
61). Such properties could offer potential for MSCs in acute and
chronic rejection after VCA. MSCs have been successfully used
in pediatric patients as rescue therapy of GVHD and repetitive
rejection of BM transplants (62).
CRITICAL ISSUES FOR MSC USE IN VCA
The success of organ transplantation and VCA is dependent on
graft acceptance in the absence of GvHD. Various induction and
maintenance regimens have been successful in controlling acute
rejection. All these drugs have their role in VCA for specific
immunosuppressive functions, but their unwarranted collateral
effects on MSCs are less well investigated.
Several studies in solid organs have reported pre-transplant,
peri-transplant, or post-transplant use of MSCs for immunomod-
ulation (63–65). However, the negative effects of the depletion
regimens that include irradiation, and polyclonal (antithymocyte
globulin/serum), or monoclonal antibodies (e.g., alemtuzumab)
on MSC recruitment, homing, and function remain to be clarified.
INTERACTION WITH IMMUNOSUPPRESSIVE DRUGS
Several immunosuppressive drugs significantly affect in vitro
activity of MSCs. Hoogduijn et al. (66) investigated the in vitro
effect of tacrolimus, rapamycin, and MPA on human MSCs and
vice versa. Exposure of MSCs to high dosages of tacrolimus was
toxic and reduced cell viability. While tacrolimus did not inhibit
proliferation rates of MSCs, rapamycin, and MPA led to a dose-
dependent reduction of proliferation and differentiation at thera-
peutic dosage levels. Unlike rapamycin, tacrolimus did not affect
the osteogenic differentiation potential of MSCs (67). The effects
of Cyclosporin A (CsA) on MSCs were insignificant. Some authors
demonstrated a synergistic immunosuppressive effect of MSCs
and MPA (68, 69). However, the immunomodulatory properties
of MSCs were antagonized by rapamycin and tacrolimus. In vivo
experiments support these findings of synergistic or opposing
effects between MSC and pharmacological immunosuppression
(68, 70). Hoogduijn’s et al (66) reported that MSCs inhibited
the suppressive effect of tacrolimus and rapamycin on alloreactive
lymphocytes but had no effect on MPA.
TIMING AND DOSAGE OF MSCs
Currently, there is no consensus on dosing and timing of admin-
istration of MSCs in cell-based VCA protocols. Experimental
studies indicate that the dosage of MSCs showing beneficial results
ranges from 5× 105 to 5× 107 cells/kg body weight and time point
(Table 1). In rats, the total amount of BM-MSCs administered
over time was 6−10× 106 cells, whereas in pigs total amounts
from 5 to 12.5× 107. BM-MSCs were used. In a study utilizing
AD-MSCs, as many as 24× 106 cells/kg bodyweight were adminis-
tered over three time points (58, 59, 71). MSCs were administered
as early as day −30 to as late as +21 relative to transplantation
or at different frequency in the interim (57–59). The time point
was chosen with regards to the desired effect such as induction,
immunomodulation, or support of BM engraftment.
HOMING OF MSCs/CHIMERISM
Eggenhofer et al. (72) recently reported a murine study reduced life
span of intravenously delivered cultured MSCs due to entrapment
in the lung capillaries or liver sinusoids. Others have shown distri-
bution to other organs like kidney and spleen, BM, and peripheral
blood (73). Kuo et al. (58) demonstrated recruitment and homing
of MSCs to perivascular sites with long-term survival in VCA mod-
els. In addition peripheral blood chimerism after VCA with MSC-
co-transplantation was demonstrated in pig and rat models (57–
59). Indeed, the first-pass clearance of MSCs in lung and liver may
be an obstacle for these cell therapies (74, 75). Several strategies
including vasodilation, co-transplantation, and repetitive infu-
sions have been suggested to increase cell passage. Freshly isolated
MSCs have been shown to be superior to culture-expanded MSCs
in terms of lower entrapment potential due to smaller size as well
as better homing potential (76). They are found in high number
in sites of trauma and ischemia after several days (77).
CULTURED MSCs
For therapeutic indications, MSCs need to be expanded in culture
to achieve sufficient numbers for transplantation. Karp and Leng
(78) reported that the culture medium and conditions are likely
to influence the properties of MSCs as well as their morphol-
ogy (79, 80). The number of passages inversely correlates with
the number of surface antigens and homing potential (81–84).
Cultured MSCs may be morphologically indistinguishable from
fibroblasts and even show similar cell-surface markers, differen-
tiation potential, and immunologic properties (80). Multiple cell
passages not only affect proliferation and differentiation but also
alter cell-surface antigens and cytokine production (85, 86). To our
knowledge, there is no study to date on the immunomodulatory
potential of long-term-cultured MSCs. In our view, short-term
culture of MSCs (<P3) and freshly isolated MSCs must be given
preference in cell therapy protocols until we gain more insights
into the properties of expanded MSCs.
MSCs IN VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION
Only a few groups have advocated the use of BM-MSCs or
AD-MSCs for immunomodulatory strategies in VCA (Table 1).
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Table 1 | Overview of the currently available experimental literature on MSC based cellular therapy for immunomodulation inVCA.
Reference Type of
graft
Species MSCs
amount/type
MSC
application
Induction
regimen
Immuno-
suppression
Main outcome
Pan et al. (59) Hindlimb Rat 107 BM-MSCs
(allogeneic)
Day −30 Irradiation,
ALS, BMT
Rapamycin Chimerism in peripheral blood
Tolerance (>100 days)
Protection against GvHD
Kuo et al. (58) Hindlimb Pig 107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
Irradiation,
BMT
Cyclosporin Perivascular MSC engraftment (graft)
Chimerism in peripheral blood
Tolerance (>200 days)
Protection against GvHD
Treg ⇑
Kuo et al. (87) Hindlimb Pig 107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
Irradiation Cyclosporin Tolerance (>120 days)
Treg ⇑
Kuo et al. (57) Hindlimb Rat 2×106 AD-MSCs
(allogeneic)
Day +7, +14,
+21
ALS Cyclosporin Tolerance (>150 days)
Chimerism peripheral blood
Treg ⇑
IL-10 ⇑
Kuo et al. (88) Face Pig 2.5×107 BM-MSCs
(allogeneic)
Day −1, +3,
+7, +14, +21
N/A Cyclosporin Treg ⇑
IL-10 ⇑
Aksu et al. (71) Skin flap Rat 2–3×106 (repetitive)
BM-MSCs
(syngeneic)
Days 0, +7,
+14, and +21
Irradiation
BMT
(repetitive)
Cyclosporin Syngeneic MSCs limit toxicity of
allogeneic BMT
Prolongation of tolerance
Enhanced mixed chimerism
Despite growing enthusiasm, the basic experience is limited to few
experimental studies with MSCs. Aksu et al. (71) reported that
co-administration of host BM-MSCs with unmodified donor BM
and immunosuppression (CsA+ irradiation) enabled prolonged
survival of full MHC mismatched rodent vascularized skin grafts
with generation of mixed chimerism and absence of GvHD. Out-
comes positively correlated with number of times the BM-MSCs
were administered. Pan et al. (59) reported a rat hindlimb VCA
model where limb transplants were performed a month after
conditioning with total body irradiation, and anti-lymphocyte-
serum followed by allogeneic BM-MSC and BM infusion. This
resulted in stable chimerism, donor specific tolerance, and no
GvHD. Allogeneic BM-MSC transplantation with or without co-
transplantation of BM has been shown to be successful in prolon-
gation (>200 days) of pig limb allograft survival after irradiation
and CsA treatment (58, 87). Repetitive high dose BM-MSC treat-
ment was also successful in prolonging survival in a pig hemi-facial
transplantation model without conditioning therapy (88). The
authors reported only mild rejection of the graft (Grade I–II),
improved under CsA treatment. The positive effects of BM-MSCs
on rejection grades were correlated to IL-10 upregulation and Treg
induction. Despite the prolongation, all grafts succumbed within
90 days. In a different approach, Kuo et al. (57) administered three
fold numbers of AD-MSCs under temporary immunosuppres-
sion in a rat hindlimb allotransplantation model. After cessation
of immunosuppression, this regimen prolonged allograft survival
significantly with stable tolerance in 89% for>150 days. Treg pop-
ulations were significantly increased and elevated donor lymphoid
cell counts (RT1n) resulted in stable peripheral blood chimerism
until endpoint. The same group conducted a study in a swine
hindlimb allotransplantation model using BM-MSCs, irradiation,
and short-term CsA. They were able to demonstrate prolongation
of the survival (>100 days in 67%) and an increase of the Treg
population.
CONCLUSION
Taken together, emerging literature evidence highlights the poten-
tial promise of MSC based cellular therapies for immunomod-
ulation and neurodegeneration in VCA. Extensive experimental
and clinical studies in the areas of solid organ transplantation,
hematopoietic stem cell co-transplantation and autoimmune dis-
ease underscore the relevance and impact of MSC based therapies
in VCA. Traditionally, the chief obstacle hampering application
of BM-MSCs has been the limited cell yield and requirement for
donor cell expansion. The high cell yields of AD-MSCs from adi-
pose sources obtained through easy, fairly non-invasive techniques
have enabled expeditious cell processing, thus expanding the clini-
cal feasibility of these therapies. These advantages, combined with
the insights supporting the superior immunomodulatory poten-
tial of AD-MSCs versus BM-MSCs truly advocate adipose-based
cellular therapies. The higher cell yields also facilitate repetitive
infusion both systemically and locally in the graft. Freshly iso-
lated AD-MSCs can overcome the loss of viability and entrapment
during the first-pass phenomenon in the capillary systems of the
lung. Importantly, MSCs mediate paracrine effects on remote tis-
sues through specific cytokines, chemokines, and growth factors.
It still remains to be defined if such paracrine effects mediate
also tolerogenic or immunomodulatory effects in VCA or other
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applications. Future protocols should carefully address the dosing
and timing of MSC administration and the effects of conditioning
regimens and maintenance immunosuppression on function of
these cells. Most notably, the effect of MSC based strategies on
nerve regeneration, critical for functional outcomes in VCA offers
an uncharted area of investigation. Thus far, only one donor
BM cell-based protocol has been clinically evaluated in human
upper extremity VCA (Pittsburgh Protocol) and involves mega-
dose donor derived BM infusion after at day 11–14 after surgery
(89). Insights into the impact of such protocols in minimizing the
need for dosing, frequency, and duration of immunosuppression
are just emerging. Meanwhile, we must continue to explore the
multifaceted potential of MSCs in experimental VCA to further
fine tune standard protocols as used in conventional VCA or solid
organ transplantation. The true clinical scope and impact of dis-
parate VCA strategies will only be realized when such protocols
enable optimization of the functional and immunological benefits
of these novel reconstructive procedures while reducing long-term
risk of lifelong immunosuppression.
ACKNOWLEDGMENTS
The authors have no financial interests. Jan A. Plock and Jonas
T. Schnider are recipients of Swiss National Science foundation
funding.
REFERENCES
1. Petruzzo P, Lanzetta M, Dubernard
JM, Landin L, Cavadas P, Mar-
greiter R, et al. The international
registry on hand and composite
tissue transplantation. Transplanta-
tion (2010) 90:1590–4. doi:10.1097/
TP.0b013e3181ff1472
2. Petruzzo P, Kanitakis J, Badet L,
Pialat JB, Boutroy S, Charpulat
R, et al. Long-term follow-up in
composite tissue allotransplanta-
tion: in-depth study of five (hand
and face) recipients. Am J Trans-
plant (2011) 11:808–16. doi:10.
1111/j.1600-6143.2011.03469.x
3. Petruzzo P, Testelin S, Kanitakis J,
Badet L, Lengele B, Girbon JP, et
al. First human face transplantation:
5 years outcomes. Transplantation
(2012) 93:236–40. doi:10.1097/TP.
0b013e31823d4af6
4. Singer NG, Caplan AI. Mes-
enchymal stem cells: mechanisms
of inflammation. Annu Rev
Pathol (2011) 6:457–78. doi:
10.1146/annurev-pathol-011110-
130230
5. English K. Mechanisms of
mesenchymal stromal cell
immunomodulation. Immunol
Cell Biol (2013) 91:19–26. doi:
10.1038/icb.2012.56
6. Izadpanah R, Trygg C, Patel B,
Kriedt C, Dufour J, Gimble JM, et al.
Biologic properties of mesenchymal
stem cells derived from bone
marrow and adipose tissue. J Cell
Biochem (2006) 99:1285–97. doi:10.
1002/jcb.20904
7. Liu TM, Martina M,
Hutmacher DW, Hui JH, Lee
EH, Lim B. Identification of
common pathways mediating
differentiation of bone marrow-
and adipose tissue-derived human
mesenchymal stem cells into
three mesenchymal lineages.
Stem Cells (2007) 25:750–60. doi:
10.1634/stemcells.2006-0394
8. Noel D, Caton D, Roche S, Bony C,
Lehmann S, Casteilla L, et al. Cell
specific differences between human
adipose-derived and mesenchymal-
stromal cells despite similar differ-
entiation potentials. Exp Cell Res
(2008) 314:1575–84. doi:10.1016/j.
yexcr.2007.12.022
9. Bartholomew A, Sturgeon C,
Siatskas M, Ferrer K, Mcintosh
K, Patil S, et al. Mesenchymal
stem cells suppress lymphocyte
proliferation in vitro and prolong
skin graft survival in vivo. Exp
Hematol (2002) 30:42–8. doi:
10.1016/S0301-472X(01)00769-X
10. De Ugarte DA, Morizono K, Elbar-
bary A, Alfonso Z, Zuk PA, Zhu
M, et al. Comparison of multi-
lineage cells from human adipose
tissue and bone marrow. Cells Tis-
sues Organs (2003) 174:101–9. doi:
10.1159/000071150
11. Melief SM, Zwaginga JJ, Fibbe WE,
Roelofs H. Adipose tissue-derived
multipotent stromal cells have a
higher immunomodulatory capac-
ity than their bone marrow-derived
counterparts. Stem Cells Transl Med
(2013) 2:455–63. doi:10.5966/sctm.
2012-0184
12. Cui L, Yin S, Liu W, Li N, Zhang W,
Cao Y. Expanded adipose-derived
stem cells suppress mixed lym-
phocyte reaction by secretion of
prostaglandin E2. Tissue Eng (2007)
13:1185–95. doi:10.1089/ten.2006.
0315
13. Fang B, Song Y, Lin Q, Zhang Y,
Cao Y, Zhao RC, et al. Human
adipose tissue-derived mesenchy-
mal stromal cells as salvage therapy
for treatment of severe refractory
acute graft-vs.-host disease in two
children. Pediatr Transplant (2007)
11:814–7. doi:10.1111/j.1399-3046.
2007.00780.x
14. Wan CD, Cheng R, Wang HB, Liu T.
Immunomodulatory effects of mes-
enchymal stem cells derived from
adipose tissues in a rat orthotopic
liver transplantation model. Hepa-
tobiliary Pancreat Dis Int (2008)
7:29–33.
15. Constantin G, Marconi S, Rossi B,
Angiari S, Calderan L, Anghileri
E, et al. Adipose-derived mes-
enchymal stem cells ameliorate
chronic experimental autoim-
mune encephalomyelitis. Stem
Cells (2009) 27:2624–35. doi:
10.1002/stem.194
16. Gonzalez MA, Gonzalez-Rey E, Rico
L, Buscher D, Delgado M. Treat-
ment of experimental arthritis by
inducing immune tolerance with
human adipose-derived mesenchy-
mal stem cells. Arthritis Rheum
(2009) 60:1006–19. doi:10.1002/art.
24405
17. Gonzalez-Rey E, Anderson P, Gon-
zalez MA, Rico L, Buscher D, Del-
gado M. Human adult stem cells
derived from adipose tissue pro-
tect against experimental colitis and
sepsis. Gut (2009) 58:929–39. doi:
10.1136/gut.2008.168534
18. Crop MJ, Baan CC, Korevaar SS,
Ijzermans JN, Pescatori M, Stubbs
AP, et al. Inflammatory conditions
affect gene expression and function
of human adipose tissue-derived
mesenchymal stem cells. Clin Exp
Immunol (2010) 162:474–86. doi:
10.1111/j.1365-2249.2010.04256.x
19. Gonzalez-Rey E, Gonzalez MA,
Varela N, O’Valle F, Hernandez-
Cortes P, Rico L, et al. Human
adipose-derived mesenchymal stem
cells reduce inflammatory and T cell
responses and induce regulatory T
cells in vitro in rheumatoid arthritis.
Ann Rheum Dis (2010) 69:241–8.
doi:10.1136/ard.2008.101881
20. Engela AU, Baan CC, Dor FJ,
Weimar W, Hoogduijn MJ. On the
interactions between mesenchymal
stem cells and regulatory T cells for
immunomodulation in transplan-
tation. Front Immunol (2012) 3:126.
doi:10.3389/fimmu.2012.00126
21. Jones BJ, Mctaggart SJ. Immuno-
suppression by mesenchymal stro-
mal cells: from culture to clinic.
Exp Hematol (2008) 36:733–41. doi:
10.1016/j.exphem.2008.03.006
22. Griffin MD, Ritter T, Mahon
BP. Immunological aspects
of allogeneic mesenchymal
stem cell therapies. Hum Gene
Ther (2010) 21:1641–55. doi:
10.1089/hum.2010.156
23. Parekkadan B, Milwid JM. Mes-
enchymal stem cells as therapeutics.
Annu Rev Biomed Eng (2010) 12:87–
117. doi:10.1146/annurev-bioeng-
070909-105309
24. Weng JY, Du X, Geng SX, Peng YW,
Wang Z, Lu ZS, et al. Mesenchy-
mal stem cell as salvage treatment
for refractory chronic GVHD. Bone
Marrow Transplant (2010) 45:1732–
40. doi:10.1038/bmt.2010.195
25. Bernardo ME, Ball LM, Cometa
AM, Roelofs H, Zecca M, Avanzini
MA, et al. Co-infusion of ex vivo-
expanded, parental MSCs prevents
life-threatening acute GVHD, but
does not reduce the risk of graft
failure in pediatric patients under-
going allogeneic umbilical cord
blood transplantation. Bone Mar-
row Transplant (2011) 46:200–7.
doi:10.1038/bmt.2010.87
26. Lee WP, Yaremchuk MJ, Pan YC,
Randolph MA, Tan CM, Weiland
AJ. Relative antigenicity of compo-
nents of a vascularized limb allo-
graft. Plast Reconstr Surg (1991)
87:401–11. doi:10.1097/00006534-
199103000-00001
27. Djouad F, Charbonnier LM, Bouffi
C, Louis-Plence P, Bony C, Appa-
railly F, et al. Mesenchymal stem
cells inhibit the differentiation
of dendritic cells through an
interleukin-6-dependent mecha-
nism. Stem Cells (2007) 25:2025–32.
doi:10.1634/stemcells.2006-0548
28. English K, Barry FP, Mahon BP.
Murine mesenchymal stem cells
suppress dendritic cell migration,
maturation and antigen presenta-
tion. Immunol Lett (2008) 115:50–
8. doi:10.1016/j.imlet.2007.10.002
29. Li M, Sun K, Welniak LA, Murphy
WJ. Immunomodulation and phar-
macological strategies in the treat-
ment of graft-versus-host disease.
Expert Opin Pharmacother (2008)
9:2305–16. doi:10.1517/14656566.
9.13.2305
www.frontiersin.org July 2013 | Volume 4 | Article 175 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plock et al. MSCs in vascularized composite allotransplantation
30. Zhang X, Jiao C, Zhao S. Role
of mesenchymal stem cells in
immunological rejection of
organ transplantation. Stem
Cell Rev (2009) 5:402–9. doi:
10.1007/s12015-009-9076-y
31. Selmani Z, Naji A, Zidi I, Favier
B, Gaiffe E, Obert L, et al. Human
leukocyte antigen-G5 secretion by
human mesenchymal stem cells is
required to suppress T lymphocyte
and natural killer function and to
induce CD4+CD25highFOXP3+
regulatory T cells. Stem
Cells (2008) 26:212–22. doi:
10.1634/stemcells.2007-0554
32. De Miguel MP, Fuentes-Julian
S, Blazquez-Martinez A, Pas-
cual CY, Aller MA, Arias J, et
al. Immunosuppressive proper-
ties of mesenchymal stem cells:
advances and applications. Curr
Mol Med (2012) 12:574–91. doi:
10.2174/156652412800619950
33. Nasef A, Mathieu N, Chapel A,
Frick J, Francois S, Mazurier C, et
al. Immunosuppressive effects of
mesenchymal stem cells: involve-
ment of HLA-G. Transplantation
(2007) 84:231–7. doi:10.1097/01.tp.
0000267918.07906.08
34. Selmani Z, Naji A, Gaiffe E,
Obert L, Tiberghien P, Rouas-
Freiss N, et al. HLA-G is a cru-
cial immunosuppressive molecule
secreted by adult human mes-
enchymal stem cells. Transplanta-
tion (2009) 87:S62–6. doi:10.1097/
TP.0b013e3181a2a4b3
35. English K, Ryan JM, Tobin L, Mur-
phy MJ, Barry FP, Mahon BP. Cell
contact, prostaglandin E(2) and
transforming growth factor beta 1
play non-redundant roles in human
mesenchymal stem cell induction
of CD4+CD25(High) forkhead box
P3+ regulatory T cells. Clin Exp
Immunol (2009) 156:149–60. doi:
10.1111/j.1365-2249
36. Franquesa M, Hoogduijn
MJ, Bestard O, Grinyo JM.
Immunomodulatory effect of
mesenchymal stem cells on B cells.
Front Immunol (2012) 3:212. doi:
10.3389/fimmu.2012.00212
37. Liu G, Cheng Y, Guo S, Feng Y,
Li Q, Jia H, et al. Transplanta-
tion of adipose-derived stem cells
for peripheral nerve repair. Int J
Mol Med (2011) 28:565–72. doi:
10.3892/ijmm.2011.725
38. Lopatina T, Kalinina N, Karagyaur
M, Stambolsky D, Rubina K,
Revischin A, et al. Adipose-derived
stem cells stimulate regeneration of
peripheral nerves: BDNF secreted
by these cells promotes nerve heal-
ing and axon growth de novo. PLoS
ONE (2011) 6:e17899. doi:10.1371/
journal.pone.0017899
39. Carriel V, Garrido-Gomez J,
Hernandez-Cortes P, Garzon I,
Garcia-Garcia S, Saez-Moreno JA,
et al. Combination of fibrin-agarose
hydrogels and adipose-derived mes-
enchymal stem cells for peripheral
nerve regeneration. J Neural
Eng (2013) 10:026022. doi:
10.1088/1741-2560/10/2/026022
40. Marconi S, Castiglione G, Turano
E, Bissolotti G, Angiari S, Farinazzo
A, et al. Human adipose-derived
mesenchymal stem cells systemi-
cally injected promote peripheral
nerve regeneration in the mouse
model of sciatic crush. Tissue Eng
Part A (2012) 18:1264–72. doi:10.
1089/ten.TEA.2011.0491
41. Chen CJ, Ou YC, Liao SL, Chen
WY, Chen SY, Wu CW, et al. Trans-
plantation of bone marrow stro-
mal cells for peripheral nerve repair.
Exp Neurol (2007) 204:443–53. doi:
10.1016/j.expneurol.2006.12.004
42. Sbano P, Cuccia A, Mazzanti B,
Urbani S, Giusti B, Lapini I, et
al. Use of donor bone marrow
mesenchymal stem cells for treat-
ment of skin allograft rejection in
a preclinical rat model. Arch Der-
matol Res (2008) 300:115–24. doi:
10.1007/s00403-007-0827-9
43. Solari MG, Srinivasan S, Boumaza
I, Unadkat J, Harb G, Garcia-
Ocana A, et al. Marginal mass
islet transplantation with autolo-
gous mesenchymal stem cells pro-
motes long-term islet allograft sur-
vival and sustained normoglycemia.
J Autoimmun (2009) 32:116–24.
doi:10.1016/j.jaut.2009.01.003
44. Wu GD, Nolta JA, Jin YS, Barr
ML, Yu H, Starnes VA, et al.
Migration of mesenchymal stem
cells to heart allografts during
chronic rejection. Transplantation
(2003) 75:679–85. doi:10.1097/01.
TP.0000048488.35010.95
45. Inoue S, Popp FC, Koehl GE, Piso
P, Schlitt HJ, Geissler EK, et al.
Immunomodulatory effects of mes-
enchymal stem cells in a rat organ
transplant model. Transplantation
(2006) 81:1589–95. doi:10.1097/01.
tp.0000209919.90630.7b
46. Zhou HP, Yi DH, Yu SQ, Sun GC,
Cui Q, Zhu HL, et al. Adminis-
tration of donor-derived mesenchy-
mal stem cells can prolong the sur-
vival of rat cardiac allograft. Trans-
plant Proc (2006) 38:3046–51. doi:
10.1016/j.transproceed.2006.10.002
47. Itakura S, Asari S, Rawson J, Ito
T, Todorov I, Liu CP, et al. Mes-
enchymal stem cells facilitate the
induction of mixed hematopoietic
chimerism and islet allograft toler-
ance without GVHD in the rat. Am
J Transplant (2007) 7:336–46. doi:
10.1111/j.1600-6143.2006.01643.x
48. Hong ZF, Huang XJ, Yin ZY,
Zhao WX, Wang XM. Immuno-
suppressive function of bone mar-
row mesenchymal stem cells on
acute rejection of liver allografts in
rats. Transplant Proc (2009) 41:403–
9. doi:10.1016/j.transproceed.2008.
10.020
49. Popp FC, Renner P, Eggenhofer
E, Slowik P, Geissler EK, Piso
P, et al. Mesenchymal stem
cells as immunomodulators
after liver transplantation. Liver
Transpl (2009) 15:1192–8. doi:
10.1002/lt.21862
50. Crop MJ, Baan CC, Korevaar SS, Ijz-
ermans JN, Weimar W, Hoogduijn
MJ. Human adipose tissue-derived
mesenchymal stem cells induce
explosive T-cell proliferation. Stem
Cells Dev (2010) 19:1843–53. doi:
10.1089/scd.2009.0368
51. Di Ianni M, Del Papa B, De Ioanni
M, Moretti L, Bonifacio E, Cecchini
D, et al. Mesenchymal cells recruit
and regulate T regulatory cells. Exp
Hematol (2008) 36:309–18. doi:10.
1016/j.exphem.2007.11.007
52. Duffy MM, Ritter T, Ceredig R,
Griffin MD. Mesenchymal stem cell
effects on T-cell effector pathways.
Stem Cell Res Ther (2011) 2:34. doi:
10.1186/scrt75
53. Casiraghi F, Azzollini N, Todeschini
M, Cavinato RA, Cassis P, Solini S,
et al. Localization of mesenchymal
stromal cells dictates their immune
or proinflammatory effects in kid-
ney transplantation. Am J Trans-
plant (2012) 12:2373–83. doi:10.
1111/j.1600-6143.2012.04115.x
54. De Girolamo L, Lucarelli E, Alessan-
dri G, Avanzini MA, Bernardo
ME, Biagi E, et al. Mesenchymal
stem/stromal cells: a new “cells as
drugs” paradigm. Efficacy and crit-
ical aspects in cell therapy. Curr
Pharm Des (2013) 19:2459–73. doi:
10.2174/1381612811319130015
55. Tan J, Wu W, Xu X, Liao L, Zheng F,
Messinger S, et al. Induction therapy
with autologous mesenchymal stem
cells in living-related kidney trans-
plants: a randomized controlled
trial. JAMA (2012) 307:1169–77.
doi:10.1001/jama.2012.316
56. Le Blanc K, Frassoni F, Ball L,
Locatelli F, Roelofs H, Lewis I,
et al. Mesenchymal stem cells
for treatment of steroid-resistant,
severe, acute graft-versus-host dis-
ease: a phase II study. Lancet
(2008) 371:1579–86. doi:10.1016/
S0140-6736(08)60690-X
57. Kuo YR, Chen CC, Goto S,
Lee IT, Huang CW, Tsai CC,
et al. Modulation of immune
response and T-cell regulation by
donor adipose-derived stem cells
in a rodent hind-limb allotrans-
plant model. Plast Reconstr Surg
(2011) 128:661e–72. doi:10.1097/
PRS.0b013e318230c60b
58. Kuo YR, Goto S, Shih HS, Wang
FS, Lin CC, Wang CT, et al. Mes-
enchymal stem cells prolong com-
posite tissue allotransplant survival
in a swine model. Transplantation
(2009) 87:1769–77. doi:10.1097/TP.
0b013e3181a664f1
59. Pan H, Zhao K, Wang L, Zheng Y,
Zhang G, Mai H, et al. Mesenchy-
mal stem cells enhance the induc-
tion of mixed chimerism and tol-
erance to rat hind-limb allografts
after bone marrow transplantation.
J Surg Res (2010) 160:315–24. doi:
10.1016/j.jss.2008.09.027
60. Bernardo ME, Fibbe WE. Safety
and efficacy of mesenchymal stro-
mal cell therapy in autoimmune
disorders. Ann N Y Acad Sci
(2012) 1266:107–17. doi:10.1111/j.
1749-6632.2012.06667.x
61. Figueroa FE, Carrion F, Villanueva
S, Khoury M. Mesenchymal stem
cell treatment for autoimmune
diseases: a critical review. Biol
Res (2012) 45:269–77. doi:10.1590/
S0716-97602012000300008
62. Lawitschka A, Ball L, Peters C.
Nonpharmacologic treatment
of chronic graft-versus-host
disease in children and ado-
lescents. Biol Blood Marrow
Transplant (2012) 18:S74–81. doi:
10.1016/j.bbmt.2011.11.001
63. Casiraghi F, Azzollini N, Cassis P,
Imberti B, Morigi M, Cugini D, et
al. Pretransplant infusion of mes-
enchymal stem cells prolongs the
survival of a semiallogeneic heart
transplant through the generation
of regulatory T cells. J Immunol
(2008) 181:3933–46.
64. Ge W, Jiang J, Baroja ML, Arp
J, Zassoko R, Liu W, et al. Infu-
sion of mesenchymal stem cells and
rapamycin synergize to attenuate
alloimmune responses and promote
cardiac allograft tolerance. Am J
Transplant (2009) 9:1760–72. doi:
10.1111/j.1600-6143.2009.02721.x
65. Oh JY, Lee RH,Yu JM, Ko JH, Lee HJ,
Ko AY, et al. Intravenous mesenchy-
mal stem cells prevented rejection
of allogeneic corneal transplants
by aborting the early inflammatory
response. Mol Ther (2012) 20:2143–
52. doi:10.1038/mt.2012.165
66. Hoogduijn MJ, Crop MJ, Kore-
vaar SS, Peeters AM, Eijken M,
Frontiers in Immunology | Immunological Tolerance July 2013 | Volume 4 | Article 175 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plock et al. MSCs in vascularized composite allotransplantation
Maat LP, et al. Susceptibility of
human mesenchymal stem cells
to tacrolimus, mycophenolic acid,
and rapamycin. Transplantation
(2008) 86:1283–91. doi:10.1097/TP.
0b013e31818aa536
67. Isomoto S, Hattori K, Ohgushi H,
Nakajima H, Tanaka Y, Takakura
Y. Rapamycin as an inhibitor of
osteogenic differentiation in bone
marrow-derived mesenchymal stem
cells. J Orthop Sci (2007) 12:83–8.
doi:10.1007/s00776-006-1079-9
68. Buron F, Perrin H, Malcus C,
Hequet O, Thaunat O, Kholopp-
Sarda MN, et al. Human mesenchy-
mal stem cells and immunosup-
pressive drug interactions in allo-
geneic responses: an in vitro study
using human cells. Transplant Proc
(2009) 41:3347–52. doi:10.1016/j.
transproceed.2009.08.030
69. Eggenhofer E, Steinmann JF, Renner
P, Slowik P, Piso P, Geissler EK, et
al. Mesenchymal stem cells together
with mycophenolate mofetil inhibit
antigen presenting cell and T cell
infiltration into allogeneic heart
grafts. Transpl Immunol (2011)
24:157–63. doi:10.1016/j.trim.2010.
12.002
70. Eggenhofer E, Renner P, Soeder Y,
Popp FC, Hoogduijn MJ, Geissler
EK, et al. Features of synergism
between mesenchymal stem cells
and immunosuppressive drugs in
a murine heart transplantation
model. Transpl Immunol (2011)
25:141–7. doi:10.1016/j.trim.2011.
06.002
71. Aksu AE, Horibe E, Sacks J, Ikeguchi
R, Breitinger J, Scozio M, et al.
Co-infusion of donor bone marrow
with host mesenchymal stem cells
treats GVHD and promotes vascu-
larized skin allograft survival in rats.
Clin Immunol (2008) 127:348–58.
doi:10.1016/j.clim.2008.02.003
72. Eggenhofer E, Benseler V, Kroe-
mer A, Popp FC, Geissler EK,
Schlitt HJ, et al. Mesenchymal
stem cells are short-lived and do
not migrate beyond the lungs
after intravenous infusion. Front
Immunol (2012) 3:297. doi:10.3389/
fimmu.2012.00297
73. Gao J, Dennis JE, Muzic RF,
Lundberg M, Caplan AI. The
dynamic in vivo distribution of
bone marrow-derived mesenchy-
mal stem cells after infusion. Cells
Tissues Organs (2001) 169:12–20.
doi:10.1159/000047856
74. Schrepfer S, Deuse T, Reichen-
spurner H, Fischbein MP, Robbins
RC, Pelletier MP. Stem cell trans-
plantation: the lung barrier. Trans-
plant Proc (2007) 39:573–6. doi:10.
1016/j.transproceed.2006.12.019
75. Fischer UM, Harting MT, Jimenez
F, Monzon-Posadas WO, Xue H,
Savitz SI, et al. Pulmonary pas-
sage is a major obstacle for intra-
venous stem cell delivery: the pul-
monary first-pass effect. Stem Cells
Dev (2009) 18:683–92. doi:10.1089/
scd.2008.0253
76. Rombouts WJ, Ploemacher RE. Pri-
mary murine MSC show highly effi-
cient homing to the bone marrow
but lose homing ability following
culture. Leukemia (2003) 17:160–
70. doi:10.1038/sj.leu.2402763
77. Schlosser S, Dennler C, Schweizer R,
Eberli D, Stein JV, Enzmann V, et
al. Paracrine effects of mesenchymal
stem cells enhance vascular regen-
eration in ischemic murine skin.
Microvasc Res (2012) 83:267–75.
doi:10.1016/j.mvr.2012.02.011
78. Karp JM, Leng Teo GS. Mesenchy-
mal stem cell homing: the devil is
in the details. Cell Stem Cell (2009)
4:206–16. doi:10.1016/j.stem.2009.
02.001
79. Wagner W, Horn P, Castoldi M,
Diehlmann A, Bork S, Saffrich R,
et al. Replicative senescence of mes-
enchymal stem cells: a continu-
ous and organized process. PLoS
ONE (2008) 3:e2213. doi:10.1371/
journal.pone.0002213
80. Hematti P. Mesenchymal stro-
mal cells and fibroblasts:
a case of mistaken iden-
tity? Cytotherapy (2012) 14:
516–21. doi:10.3109/14653249.
2012.677822
81. Wynn RF, Hart CA, Corradi-Perini
C, O’Neill L, Evans CA, Wraith JE, et
al. A small proportion of mesenchy-
mal stem cells strongly expresses
functionally active CXCR4 receptor
capable of promoting migration
to bone marrow. Blood (2004)
104:2643–5. doi:10.1182/blood-
2004-02-0526
82. Ruster B, Gottig S, Ludwig RJ, Bis-
trian R, Muller S, Seifried E, et
al. Mesenchymal stem cells display
coordinated rolling and adhesion
behavior on endothelial cells. Blood
(2006) 108:3938–44. doi:10.1182/
blood-2006-05-025098
83. Phinney DG, Prockop DJ.
Concise review: mesenchy-
mal stem/multipotent stromal
cells: the state of transdiffer-
entiation and modes of tissue
repair – current views. Stem
Cells (2007) 25:2896–902. doi:
10.1634/stemcells.2007-0637
84. Sackstein R, Merzaban JS, Cain DW,
Dagia NM, Spencer JA, Lin CP, et al.
Ex vivo glycan engineering of CD44
programs human multipotent mes-
enchymal stromal cell trafficking to
bone. Nat Med (2008) 14:181–7.
doi:10.1038/nm1703
85. Vacanti V, Kong E, Suzuki G, Sato
K, Canty JM, Lee T. Phenotypic
changes of adult porcine mesenchy-
mal stem cells induced by prolonged
passaging in culture. J Cell Physiol
(2005) 205:194–201. doi:10.1002/
jcp.20376
86. Wagner W, Ho AD, Zenke M. Dif-
ferent facets of aging in human
mesenchymal stem cells. Tissue Eng
Part B Rev (2010) 16:445–53. doi:
10.1089/ten.TEB.2009.0825
87. Kuo YR, Chen CC, Shih HS, Goto
S, Huang CW, Wang CT, et al.
Prolongation of composite tissue
allotransplant survival by treatment
with bone marrow mesenchymal
stem cells is correlated with
T-cell regulation in a swine
hind-limb model. Plast Reconstr
Surg (2011) 127:569–79. doi:
10.1097/PRS.0b013e318200a92c
88. Kuo YR, Chen CC, Goto S,
Huang YT, Wang CT, Tsai CC,
et al. Immunomodulatory effects
of bone marrow-derived mesenchy-
mal stem cells in a swine hemi-
facial allotransplantation model.
PLoS ONE (2012) 7:e35459. doi:
10.1371/journal.pone.0035459
89. Schneeberger S, Gorantla VS, Bran-
dacher G, Zeevi A, Demetris
AJ, Lunz JG, et al. Upper-
extremity transplantation using
a cell-based protocol to mini-
mize immunosuppression. Ann
Surg (2013) 257:345–51. doi:
10.1097/SLA.0b013e31826d90bb
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 06 May 2013; paper pending
published: 27 May 2013; accepted: 18
June 2013; published online: 23 July 2013.
Citation: Plock JA, Schnider JT, Solari
MG, Zheng XX and Gorantla VS (2013)
Perspectives on the use of mesenchymal
stem cells in vascularized composite allo-
transplantation. Front. Immunol. 4:175.
doi: 10.3389/fimmu.2013.00175
This article was submitted to Frontiers in
Immunological Tolerance, a specialty of
Frontiers in Immunology.
Copyright © 2013 Plock, Schnider,
Solari, Zheng and Gorantla. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
www.frontiersin.org July 2013 | Volume 4 | Article 175 | 7
